PFIZER LIMITED (PFIZER) AI Stock Analysis

• Market Cap: ₹218.29B
• Dividend Yield: 0.69%
• Average Volume (3M): 2.39K
• Price to Earnings (P/E): 40.2
• Beta (1Y): 0.63
• Revenue Growth: 6.13%
• EPS Growth: 35.83%
• Country: IN
• Employees: 1,721
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - General
• EPS (TTM): 40.40
• Shares Outstanding: 45,747,730
• 10 Day Avg. Volume: 3,328
• 30 Day Avg. Volume: 2,388
• PEG Ratio: 0.61
• Price to Book (P/B): 4.38
• Price to Sales (P/S): 8.09
• P/FCF Ratio: 29.23
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹6,030.00
• Price Target Upside: 23.38% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): 162.93
• Revenue Forecast (FY): ₹24.28B

• Rating: 69 Neutral
• Price Target: ₹5,053.00 ▲(3.39% Upside)
• Action: Reiterated Date: 11/01/25
• Date: Action: Reiterated 11/01/25

PFIZER LIMITED's strong financial performance is the most significant factor, supported by robust profitability and cash flow management. However, the stock's valuation appears high, and technical indicators suggest potential short-term weakness. The absence of earnings call data and corporate events means these factors do not influence the score.

Positive Factors

Balance sheet strength

Extremely low leverage and a high equity ratio provide durable financial flexibility. The strong capital structure reduces refinancing risk, supports sustained R&D or M&A spending, and the 18.2% ROE indicates efficient equity use that can underpin long-term shareholder returns and resilience in downturns.

Cash flow generation

Very strong free cash flow metrics show the business reliably converts profits into cash. High FCF growth and solid conversion ratios enable sustained reinvestment, dividend or buyback capacity, and lower reliance on external financing — a structural advantage for multi-year capital allocation.

High operating margins

Consistently elevated gross and operating margins reflect pricing power and operational efficiency. These durable profitability levels provide margin cushion against cost shocks, fund R&D and commercial expansion, and support high cash generation even if revenue growth moderates.

Negative Factors

Revenue volatility

Intermittent revenue swings reduce predictability of earnings and free cash flow, complicating capacity planning and long-term investment choices. Structural volatility may signal product-cycle or customer-concentration risks that can pressure multi-quarter guidance and capital allocation decisions.

Low dividend yield

A modest yield limits appeal to income-oriented investors seeking steady cash returns. If the company prioritizes growth over payouts, shareholders reliant on dividends face lower immediate income, constraining the investor base and making total-return delivery more dependent on durable underlying growth.

Low trading liquidity

Very low average trading volume implies limited market liquidity, which can deter larger institutional investors and increase execution costs. Structural illiquidity raises the cost of capital and can make it harder for large holders to enter or exit positions without moving prices materially.

PFIZER LIMITED Business Overview & Revenue Model

Company Description

Pfizer Limited manufactures, markets, trades in, and exports pharmaceutical products in India and internationally. The company offers its products in various therapeutic areas, including neuro/central nervous system, hormones, cardiovascular, hemophilia, anti-infectives, gynecology, pain/analgesics, orthopedic, oncology, urology, anti-parasitic, gastro intestinal, vaccines, respiratory, and vitamins/minerals/nutrients. It sells its products through a network of independent distributors primarily under various brand names. The company was incorporated in 1950 and is headquartered in Mumbai, India.

How the Company Makes Money

null

PFIZER LIMITED Financial Statement Overview

Summary

PFIZER LIMITED exhibits strong financial performance with high profitability margins, a robust balance sheet with low leverage, and excellent cash flow management. The company's consistent improvement in key financial metrics underscores its competitive standing in the industry.

Income Statement

PFIZER LIMITED has demonstrated strong profitability with a consistent gross profit margin above 60% and an increasing net profit margin, reaching 33.6% in the latest period. The company has shown a healthy EBIT margin of 48.2% and an EBITDA margin of 32.4% for the most recent year. Revenue growth has been somewhat volatile, but there is a positive growth trajectory from the previous year, indicating resilience in the market.

Balance Sheet

The company's balance sheet is robust, with a low debt-to-equity ratio of 0.03, suggesting limited leverage and a strong equity cushion. The return on equity is impressive at 18.2%, indicating efficient use of equity. Additionally, the equity ratio stands at 85.9%, showing a strong capital structure with high asset backing.

Cash Flow

PFIZER LIMITED exhibits a strong cash flow position. With a significant increase in free cash flow, the free cash flow growth rate is 165.5%. The operating cash flow to net income ratio is favorable at 0.86, and the free cash flow to net income ratio is 0.82, suggesting that the company efficiently converts profits into cash.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	23.75B	22.81B	21.93B	24.25B	26.11B	22.40B
Gross Profit	15.32B	14.66B	13.95B	15.47B	16.58B	14.38B
EBITDA	8.29B	7.05B	5.99B	7.70B	7.88B	6.70B
Net Income	8.39B	7.68B	5.51B	6.24B	6.13B	4.98B
Balance Sheet
Total Assets	46.06B	49.11B	42.29B	40.01B	39.01B	32.66B
Cash, Cash Equivalents and Short-Term Investments	27.06B	28.01B	20.27B	18.40B	16.33B	10.98B
Total Debt	898.30M	1.08B	945.40M	1.34B	1.67B	1.06B
Total Liabilities	7.57B	6.94B	6.33B	7.93B	10.36B	8.73B
Stockholders Equity	38.48B	42.17B	35.96B	32.07B	28.64B	23.93B
Cash Flow
Free Cash Flow	5.89B	6.32B	2.38B	2.91B	6.52B	4.10B
Operating Cash Flow	5.99B	6.60B	2.57B	3.56B	6.67B	4.27B
Investing Cash Flow	-1.14B	-713.40M	-713.40M	-360.50M	-5.75B	-4.69B
Financing Cash Flow	-7.75B	-2.05B	-2.05B	-3.46B	-1.81B	-15.71B

PFIZER LIMITED Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 4887.30
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:PFIZER, the sentiment is Negative. The current price of 4887.3 is above the 20-day moving average (MA) of 4862.16, above the 50-day MA of 4827.52, and below the 200-day MA of 5133.98, indicating a bearish trend. The MACD of -46.70 indicates Positive momentum. The RSI at 46.88 is Neutral, neither overbought nor oversold. The STOCH value of 51.52 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:PFIZER.

PFIZER LIMITED Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IPCALAB	74 Outperform	₹392.40B	27.58	―	0.28%	9.66%	25.79%
ALKEM	72 Outperform	₹628.64B	25.97	―	0.80%	9.32%	11.25%
ASTRAZEN	70 Outperform	₹207.61B	173.10	―	0.35%	35.14%	143.11%
PFIZER	69 Neutral	₹218.29B	40.22	―	0.69%	6.13%	35.83%
GLENMARK	53 Neutral	₹615.49B	35.61	―	0.24%	30.27%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

PFIZER LIMITED Corporate Events

Exchange Seeks Clarification from Pfizer Limited on Q2 FY2025 Financial Results

The stock exchange has requested clarification from Pfizer Limited regarding its financial results for the quarter ended 30 September 2025, specifically in relation to compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company’s response is still awaited, leaving investors and other stakeholders without further detail on the nature of the exchange’s queries or any potential implications for Pfizer Limited’s financial reporting and regulatory compliance until the clarification is provided.

Pfizer Limited to Appeal GST Demand Order of Rs 8.79 Crore

Pfizer Limited has disclosed that it received an order from the Additional Commissioner of GST & CX, Kolkata, following a GST audit for West Bengal covering financial years 2018-19 to 2022-23, raising a tax demand of Rs 4.40 crore and an equivalent penalty, totalling about Rs 8.79 crore plus interest, over alleged incorrect availment of input tax credit. The company maintains that the demand is not maintainable, plans to appeal the order, and has stated that the proceedings are not expected to have any material impact on its financials, operations or business activities, suggesting limited near-term implications for shareholders and other stakeholders.